biological behaviour of her2-low bc is dependent on hr expression
Published 2 years ago • 201 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
1:25
her2-low as a separate entity for defining her2 bc and its prognostic and biological significance
-
1:36
is her2-low a distinct subtype of breast cancer?
-
1:16
her2-low expression in breast cancer
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
7:44
treatment options for her2 breast cancer: a comprehensive guide
-
13:09
get all the info you need about her2 ve breast cancer - her2 ve breast cancer || dr liz o'riordan
-
19:46
metastatic breast cancer: what you need to know
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
1:33
questions remaining in the field of her2-low breast cancer
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
11:12
her2-low breast cancer: destiny or good science?
-
6:51
adcs for her2 and her2-low breast cancer
-
58:05
#breastpath destiny of her2/neu in the era of her2-low in 2024
-
0:31
remaining questions regarding her2-low breast cancer
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
2:30
prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis